Alternative Transition Trajectories for Complementary Asset Markets in China's Pharmaceutical Industry
As the State relinquishes its role as coordinator of interorganizational asset transfers, how do interdendent suppliers and users of complementary assets find each other and manage transactions for these assets? This study compares the emerging market structure of two different types of complementary assets in the pharmaceutical industry - new product technology (R&D) and sales and distribution (Wholesaling).
To our knowledge, this item is not available for
download. To find whether it is available, there are three
1. Check below under "Related research" whether another version of this item is available online.
2. Check on the provider's web page whether it is in fact available.
3. Perform a search for a similarly titled item that would be available.
|Date of creation:||Sep 1997|
|Date of revision:|
|Contact details of provider:|| Postal: |
Phone: +81-(0)78 803 7036
Fax: +81-(0)78 803 7059
Web page: http://www.rieb.kobe-u.ac.jp/index-e.html
More information through EDIRC
When requesting a correction, please mention this item's handle: RePEc:kob:dpaper:83. See general information about how to correct material in RePEc.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: (Office of Promoting Research Collaboration, Research Institute for Economics & Business Administration, Kobe University)
If references are entirely missing, you can add them using this form.